Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Up 106.8% in August

Jaguar Animal Health, Inc. (NASDAQ:JAGX) saw a large increase in short interest in August. As of August 31st, there was short interest totaling 242,001 shares, an increase of 106.8% from the August 15th total of 117,037 shares. Currently, 4.7% of the company’s shares are sold short. Based on an average daily trading volume, of 151,797 shares, the days-to-cover ratio is currently 1.6 days.

Analyst Ratings Changes

JAGX has been the topic of several analyst reports. Wall Street Zen upgraded Jaguar Animal Health from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Jaguar Animal Health Trading Down 31.0%

Shares of NASDAQ:JAGX traded down $0.10 during midday trading on Tuesday, reaching $0.22. 2,110,918 shares of the company’s stock were exchanged, compared to its average volume of 393,454. The stock has a market cap of $1.14 million, a price-to-earnings ratio of -0.00 and a beta of -0.07. Jaguar Animal Health has a fifty-two week low of $0.20 and a fifty-two week high of $85.40. The firm’s 50 day simple moving average is $1.02 and its two-hundred day simple moving average is $6.42. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.69 and a quick ratio of 0.40.

Shares of Jaguar Animal Health are set to reverse split on the morning of Thursday, September 17th. The 1-15 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, September 16th.

Jaguar Animal Health (NASDAQ:JAGX) last announced its earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share for the quarter, topping the consensus estimate of ($52.15) by $36.45. The company had revenue of $1.23 million for the quarter, compared to analysts’ expectations of $4.24 million.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.